EGFR and non-small cell lung carcinoma: A total of 1,046 patients were recruited, of which 526 patients with stage III/IV NSCLC were treated with EGFR-TKI in combination with KLT, while 520 patients were treated with EGFR-TKI alone, with a sample size of 46–186 in each trial.